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Introduction: Off-target effects of novel antiplatelet agents due to their potential clinical benefits are currently
an area of intensive investigation. We aimed to compare the effects of different P2Y12 antagonists on the re-
activity of vascular smooth muscle cells.
Materials and methods: Wistar rats (n=30) were pretreated with an investigated drug or placebo. Clopidogrel
(50 mg/kg, n=7), prasugrel (10 mg/kg, n=7), ticagrelor (10 mg/kg, n=7) or placebo (n=9) were adminis-
tered orally 12 and 2 hours before experiments. Constrictions of rat tail arteries induced with a stable analogue
of adenosine diphosphate (2-MeS-ADP), phenylephrine and arginine vasopressin were measured as an increase
in perfusion pressure. Effects of ticagrelor were assessed in the presence of ticagrelor (1 μM/L) added to the per-
fusion solution as this drug reversibly inhibits the P2Y12 receptor.
Results: Pretreatment with clopidogrel and prasugrel did not inhibit 2-MeS-ADP-induced contraction while tica-
grelor did. Experiments employing endothelium-deprived arteries provided similar results. Clopidogrel and
prasugrel did not influence concentration-response curves in the presence of neither phenylephrine nor argi-
nine vasopressin. The curves obtained for both vasopressors in the presence of ticagrelor and 2-MeS-ADP
were shifted to the right with a significant reduction in the maximal response.
Conclusions: Oral administration of ticagrelor, in contrast to clopidogrel and prasugrel, prevents adenosine
diphosphate-induced contraction of vascular smooth muscle cells in a rat model. Both the clinical significance
and detailed mechanism of our findings warrant further investigation.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Antiplatelet agents are the mainstay of treatment to prevent and
manage atherothrombotic events [1,2]. Furthermore, new antiplatelet
regimens overcoming many limitations of standard-dose clopidogrel
were proven to further improve clinical outcomes [3–5].
Prasugrel was introduced into clinical practise as a third generation
thienopyridinewith a rapid and effectivemetabolic activation that is as-
sociated with a faster onset of action and an increased inhibition of
platelet aggregation when compared to clopidogrel [6]. On the other
hand, ticagrelor, a cyclopentyl-triazolo-pyrimidine, constitutes a first
non-thienopyridine direct P2Y12 blocker with a faster onset and offset
of action and significantly higher inhibition of platelet aggregation as
compared to clopidogrel [7]. Furthermore, ticagrelor, in contrast to thie-
nopyridines, reversibly blocks the P2Y12 receptor therefore conferring a
great advantage when considering the substantial number of patients
with acute coronary syndromes pretreated with antiplatelet drugs
who require urgent coronary artery bypass grafting as well as the high
incidence of bleeding complications in this population. Both prasugrel
and ticagrelor posses similar antiplatelet potency and more effectively
than clopidogrel reduce the risk of subsequent myocardial infarction
and stent thrombosis [4,5].
However, unexpected mortality benefits observed in the PLATO
trial, but not in the TRITON-TIMI 38 study, led to a speculation that
benefits of ticagrelor therapy may exceed its antiplatelet properties
[5,8–10]. Therefore off-target effects of novel antiplatelet agents are
currently an area of intensive investigation.
Since P2Y12 receptors were identified on vascular smooth muscle
cells (VSMC) [11], they might represent a potential therapeutic target.
In the present study we aimed to compare vascular effects of different
P2Y12 antagonists on the reactivity of VSMC in a rat model.
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Experiments were performed on isolated, perfused Wistar rat tail
arteries. Animals were housed under a 12 h light/12 h dark cycle
and had unlimited access to food and water. Rats (n=7/per group)
were pretreated with an investigated drug or placebo (n=9). Ani-
mals, weighing 250–350 g, were narcotized by intraperitoneal injec-
tion of 120 mg urethane per 1 kg of body mass. Rats were killed by
stunning and cervical dislocation. The study protocol was approved
by the Local Ethics Committee. All studies were carried out in accor-
dance with the United StatesNIH guidelines [Guide for the Care and
Use of Laboratory Animals (1985), DHEW Publication No. (NIH)
85–23: Office of Science and Health Reports, DRR/NIH, Bethesda,
MD, U.S.A.].
Drugs and solutions
Clopidogrel (50 mg/kg), prasugrel (10 mg/kg), ticagrelor (10 mg/
kg) or placebo (normal saline) were administered orally 12 and 2
hours before the experiment. Effects of ticagrelor were assessed in
the presence of ticagrelor (1 μM/L) added to the perfusion solution
as this drug reversibly inhibits the P2Y12 receptor. Doses of investigat-
ed drugs were similar to those used in previous studies [12]. Krebs so-
lution contained NaCl (71.8 mmol/L), KCl (4.7 mmol/L), CaCl2
(1.7 mmol/L), NaHCO3 (28.4 mmol/L), MgSO4 (2.4 mmol/L), KH2PO4
(1.2 mmol/L), and glucose (11.1 mmol/L). All reagents were pur-
chased from Sigma Aldrich Chemical Company (Poznan, Poland).
Study design and conduction
After dissection from surrounding tissues, 2.5 to 3.0 cm long seg-
ment of a rat tail artery was cannulated and connected to a perfusion
device. The distal part was weighted with a 500 mg weight and the
tail was placed in a 20-mL container filled with oxygenated Krebs solu-
tion at 37 °C. The perfusion pressure was continuously measured. We
gradually increased perfusion solution flow using a peristaltic pump
up to 1 mL/min. Vessel contractions induced with phenylephrine (an
adrenergicα1 receptor agonist; PHE), arginine vasopressin (a vasopres-
sin receptor agonist, AVP) and 2-MeS-ADP (a stable analogue of adeno-
sine diphosphate - ADP) were measured as an increase in perfusion
pressure. Effects were assessed in the absence and presence of ticagre-
lor (1 μM/L) added to the perfusion solution as this drug reversibly in-
hibits the P2Y12 receptor. Experiments were performed separately on
arteries with and without vascular endothelium to assess the role of
the vascular endothelium in regulation of vascular tone in arteries de-
rived from rats pretreated with investigated drugs. Endothelium was
removed mechanically for experiments performed on arteries without
vascular endothelium. Successful endothelium removal was confirmed
by vessel contraction in the response to acetylcholine.
Data analysis and statistical procedures
Concentration-response curves (CRCs) were calculated according
to the van Rossum method. Maximal response of tissue (Emax) was
calculated as a percent of maximal response for PHE or AVP adminis-
tered in KCl solution. Half maximal effective concentration (EC50) was
estimated using classical pharmacologic methods with pD2 the nega-
tive logarithm of the EC50. We used the number of the CRC and Emax
in all calculations estimating the statistical significance (data are pre-
sented in Tables 1 and 2).
The Kolmogorov-Smirnov test was used to check normal distribu-
tion of data. Results are presented as mean values±standard devia-
tion. Statistical analysis was performed using the Newman-Keuls
test for multiple comparison of means. Value of p below 0.05 were
considered statistically significant.
Results
Effect of antiplatelet drugs on the contractility of VSMC
The reactivity of VSMC to the stable analog of ADP – 2-MeS-ADP
(10 μM/L) in the control group arteries and arteries taken from clopi-
dogrel, prasugrel and ticagrelor pretreated rats was analyzed. Re-
sponse to stimulation was analyzed in arteries with and without
Table 1
Maximal relative response for 2-MeS-ADP in the presence of antiplatelet agents in ar-
teries with and without vascular endothelium. AWE – artery without vascular endo-
thelium; PHE – phenylephrine; 2-MeS-ADP – stable analogue of adenosine
diphosphate; 1 – number of concentration-response curves used for calculations; 2 –
Emax calculated as a percent of maximal response for KCl; 3 – p calculated in compar-
ison to control values; a – p calculated in comparison to Emax for phenylephrine and
KCl.
n1 Emax [%]2 p3
Phenylephrine (10 μM/L) 12 99.0±7.1
KCl (30 mM/L) 12 100.0±6.5
2-MeS-ADP (10 μM/L) – Control 12 60.0±9.0 pb0.0001a
2-MeS-ADP (10 μM/L) – clopidogrel
pretreated rats
12 56.0±10.0 ns
2-MeS-ADP (10 μM/L) – prasugrel
pretreated rats
12 53.0±10.5 ns
2-MeS-ADP (10 μM/L) – ticagrelor
pretreated rats+ticagrelor (1 μM/L)
12 22.0±5.0 pb0.0001
AWE→2-MeS-ADP (10 μM/L) – Control 12 66.0±12.1 pb0.0001a
AWE→2-MeS-ADP (10 μM/L) –
clopidogrel pretreated rats
12 58.0±7.5 ns
AWE→2-MeS-ADP (10 μM/L) –
prasugrel pretreated rats
12 57.0±10.7 ns





Maximal relative response for phenylephrine and arginine vasopressin in the presence
of 2-MeS-ADP and antiplatelet agents. AVP – arginine vasopressin; PHE – phenyleph-
rine; 2-MeS-ADP – stable analogue of adenosine diphosphate; 1 – number of
concentration-response curves used for calculations; 2 – Emax calculated as a percent
of maximal response for KCl; 3 – p calculated in comparison to control values, a – p cal-
culated in comparison to Emax for PHE or AVP.
n1 Emax [%]2 p3
PHE (10 μM/L) 12 99.0±7.1
AVP (30 mM/L) 12 100.0±6.7
PHE (10 μM/L)+ticagrelor
(1 μM/L)
12 98.6±4.2 ns a
AVP (30 mM/L)+ticagrelor
(1 μM/L)
12 99.4±5.5 ns a
PHE+2-MeS-ADP (10 μM/L) –
control
12 112.0±13.0 pb0.0001a
PHE+2-MeS-ADP (10 μM/L) –
clopidogrel pretreated rats
12 102.0±14.0 ns
PHE+2-MeS-ADP (10 μM/L) –
prasugrel pretreated rats
12 101.0±14.5 ns
PHE+2-MeS-ADP (10 μM/L) –
ticagrelor pretreated rats+
ticagrelor (1 μM/L)
12 65.0 ±12.7 pb0.0001
AVP+2-MeS-ADP (10 μM/L) –
control
12 118.0±15.0 pb0.0001a
AVP+2-MeS-ADP (10 μM/L) –
clopidogrel pretreated rats
12 106.0±14.0 ns
AVP+2-MeS-ADP (10 μM/L) –
prasugrel pretreated rats
12 106.0±14.2 ns
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vascular endothelium. Pretreatment with clopidogrel and prasugrel
did not inhibit contraction by 2-MeS-ADP (Table 1). However, in the
presence of ticagrelor a substantial reduction in contraction, calculat-
ed as a percentage of maximal response to PHE (10−5 M/L), was
found. Experiments utilizing arteries without vascular endothelium
indicated similar results. Clopidogrel and prasugrel pretreatment
did not change the contractility of VSMC but again in the presence
of ticagrelor a significant reduction was present (Table 1).
Effect of PHE and AVP
In the second part of our CRCs for PHE (10−9 - 10−3), a preferen-
tial α1-adrenoceptor agonist, and AVP (10−10 – 10−4), a non-
selective vasopressin receptor agonist, were compared in the absence
and in the presence of 2-MeS-ADP (10 μM/L) and in the presence of
P2Y12 receptor antagonists: clopidogrel, prasugrel, and ticagrelor.
EC50 values calculated for PHE and AVP were 7.54±0.98×10−8 M/L
and 1.80±0.80×10−8 M/L, respectively. EC50 values calculated for
PHE (7.22±0.98×10−8 M/L) and AVP (1.92±0.94×10−8 M/L) in
the presence of ticagrelor (1 μM/L) did not significantly differ with
controls. The CRCs obtained for PHE and AVP in the presence of 2-
MeS-ADP were shifted to the leftward with an increase in maximal
responses (Figs. 1 and 2). Under these conditions EC50 values for
PHE and AVP were 2.60 (±1.65)×10−8 M/L (pb0.0001) and 5.10
(±1.79)×10−9 M/L (pb0.0001), respectively. Using arteries pre-
treated with clopidogrel and prasugrel there were no significant
changes in the CRCs, but in case of ticagrelol CRCs obtained for both
PHE and AVP were shifted to the right with a significant reduction
in maximal response (Figs. 1, Fig. 2, and Table 2). EC50 values calculat-
ed for PHE in the presence of clopidogrel, prasugrel and ticagrelor
were 6.85±1.30×10−8 M/L (ns), 6.92±1.10×10−8 M/L (ns) and
6.22±1.45×10−7 M/L (pb0.0001), respectively. On the other hand,
EC50 values calculated for AVP in the presence of clopidogrel, prasu-
grel and ticagrelor were 1.95±0.95×10−8 M/L (ns) 2.14±
1.18×10−8 M/L (ns) and 2.12±0.75×10−7 M/L (pb0.0001),
respectively.
Discussion
The main finding of the present study is that oral ticagrelor, in
contrast to clopidogrel and prasugrel, prevents ADP-induced VSMC
contraction in a rat model. Vasorelaxant properties of ticagrelor in
the presence of 2-MeS-ADP were also pronounced after endothelium
removal as well as when the tail arteries were perfused with PHE and
AVP.
Inhibition of ADP receptors by antiplatelet drugs became the fore-
front of therapy in coronary artery disease treated with and without
stenting [2,4,5]. ADP like other extracellular nucleotides acts through
receptors: P2X and P2Y [13]. P2X receptors are ligand-gated ion chan-
nels, whereas P2Y receptors belong to G-protein coupled receptors.
There are two different types of P2Y receptors on platelets: P2Y1
which couples to both Gq/11 and Gs and P2Y12 which couples to Gi.
After platelet activation, ADP released from granula augments aggre-
gation by stimulation of P2Y1 and P2Y12 platelet surface receptors. In
contrast to P2Y1, P2Y12 receptor has very selective tissue distribution.
Northern blot experiments conducted by Wihlborg et al indicated
that P2Y12 receptors are present not only in platelets and brain but
also in VSMC [11].
Lack of impact of thienopyridines on vessel reactivity in our study
may be explained by high instability of their active metabolites that
do not reach the systemic circulation in sufficient concentrations
[14,15]. Our observations are in line with the results of two other
studies demonstrating a neutral effect of clopidogrel pretreatment
on VSMC contractility under 2-MeS-ADP stimulation [11,12]. On the
other hand, Froldi et al observed a direct off-target effect of clopido-
grel which administered into the investigated vessel without prior
hepatic bioactivation caused relaxation of the rat tail artery [16]. In-
terestingly, André et al demonstrated in P2Y12 knockout mice a direct
impact of clopidogrel and prasugrel on the vessel wall contributing to
bleeding complications which was not mimicked by elinogrel, a direct
and reversible P2Y12 antagonist [17].
We demonstrated a potentiating effect of 2-MeS-ADP on the max-
imal contraction induced by PHE or AVP. The presence of ticagrelor
Fig. 1. CRCs obtained for PHE in the absence and presence of 2-MeS-ADP and antiplate-
let agents. Points and whiskers display mean values±standard deviations. A curve for
PHE represents a control curve for PHE+TIC and PHE+2MeSADP while a curve for
PHE+2MeSADP is a control curve for PHE+2MeSADP+CLO, PHE+2MeSADP+PRA
and PHE+2MeSADP+TIC. ADP –adenosine diphosphate; CLO – clopidogrel; CRC –
concentration-response curve; Ea/Em – % of maximal response; PHE – phenylephrine;
PRA – prasugrel; TIC – ticagrelor; * – a value of pb0.05 when compared the control
curve for points of effect between 20% and 80% of the maximal response.
Fig. 2. CRCs obtained for AVP in the absence and presence of 2-MeS-ADP and antiplate-
let agents. Points and whiskers display mean values±standard deviations. A curve for
AVP represents a control curve for AVP+TIC and AVP+2MeSADP while a curve for
AVP +2MeSADP is a control curve for AVP+2MeSADP+CLO, AVP+2MeSADP+
PRA and AVP+2MeSADP+TIC. ADP –adenosine diphosphate; AVP – arginine vaso-
pressin; CLO – clopidogrel; CRC – concentration-response curve; Ea/Em - % of maximal
response; PRA – prasugrel; TIC – ticagrelor; * – a value of pb0.05 when compared the
control curve for points of effect between 20% and 80% of the maximal response.
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did not change the maximal contraction. However, a significant inhib-
itory effect was observed in the presence of ticagrelor and 2-MeS-
ADP. These results suggest that 2-MeS-ADP may induce contraction
via P2Y12 receptor and relaxation via another ADP-dependent mech-
anism. Our observations are in line with experiments performed by
Bender et al who showed relaxation of coronary VSMC mediated by
activation of the endothelial P2Y1 receptors [18]. Similar mechanism
was also reported by Winter and Dora who were analysing effects
of ATP and ADP on the contractility of perfused isolated mesenteric
arteries [19]. This effect in our study was also present in arteries with-
out vascular endothelium that was not assessed in previous experi-
ments [18,19].
Despite the lack of benefits associatedwith inhibition of the vascular
P2Y12 receptors by clopidogrel, treatment with a high clopidogrelmain-
tenance dose of 150 mg led to significantly better flow-mediated
vasodilation in comparison with a standard therapy with 75 mg of clo-
pidogrel in the recently published ARMYDA-150 mg trial [20]. Those re-
sults are concordantwith findings of another small randomized study in
which therapywith clopidogrel dose-dependently improved endotheli-
al dysfunction in patients with coronary artery disease [21]. Investigat-
ing ADP signaling pathways in endothelial cells, Hess et al showed that
ADP elicitsmultiple phosphorylation responses, including striking alter-
ations in the phosphorylation state of endothelial nitric oxide synthase
[22]. Therefore, based on experimental data [23–25], it is believed that
clopidogrel effect on the vascular tone is predominantly attributed to
modulation of nitric oxide bioavailability.
Our findings correspond with results obtained by Högberg et al
who for the first time reported on the ability of ticagrelor, but not clo-
pidogrel, to inhibit ADP-induced contractions of VSMC in an ex vivo
study in denuded mouse aortic rings as well as in human left internal
mammary arteries [12]. We confirmed their observations in a rat
model and, for the first time, we have demonstrated that another
novel antiplatelet agent, prasugrel, behaves like clopidogrel when
assessing its vasoreactive potential under ADP stimulation.
Possible implications of the vascular P2Y12 receptor inhibition
were shown in a dog thrombosis model [26]. Adjunctive infusion of
ticagrelor, when compared to clopidogrel on top of tissue-type plas-
minogen activator and heparin, was associated with a significantly
lower reocclusion rate, lower cyclic flow variation, longer reflow du-
ration, and greater reductions in infarct sizes despite a complete
blockade of ADP-induced platelet aggregation with both regimens.
Although potential off-target effects of antiplatelet drugs are being
extensively discussed in the literature, our knowledge in this area re-
mains sparse. Previous studies suggested that clopidogrel exerts pro-
[27] and anti-inflammatory [28,29] activities as well as modulates
vascular reactivity [23–25] as presented above. A direct comparison of
clopidogrel and ticagrelor in the randomized DISPERSE 2 trial did not
reveal any differences between these two drugs with respect to the in-
flammatory biomarkers: C-reactive protein, interleukin 6, myeloperox-
idase, and soluble CD40 ligand in patients with non-ST-segment
elevation acute coronary syndromes [30]. In another study, ticagrelor
inhibited the uptake of adenosine by human erythrocytes in a canine
model and significantly enhanced the adenosine-induced increase in
coronary blood flow [31]. Furthermore, Serebruary speculates that tica-
grelor may be transformed to adenosine by degrading oxygenases and/
or cyclopropylcarbonyl radical fragmentation pathways [32]. Numerous
features related to inhibition of adenosine uptake by ticagrelor and
probably chronically increasing adenosine blood levels on ticagrelor
therapy, such as promotion of preconditioning, prevention of sudden
cardiac death, reduction of infarct size, inhibition of tumor growth,
bronchoconstriction, neurocardiogenic syncope, and up-regulation of
purine metabolism, were postulated [32].
In conclusion, ticagrelor, in contrast clopidogrel and prasugrel,
when administered orally, prevents ADP-induced contraction of
VSMC in a rat model. Both the clinical significance and detailed mech-
anism of our findings warrant further investigation.
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